Hints and tips:
...When announcing the transaction last year, Amgen had said that Horizon’s pipeline of medicines would “strongly complement” its R&D portfolio....
...“Pfizer is very good at selling but historically not renowned as having the R&D engine of a Merck or Lilly....
...Amgen has agreed to buy Horizon Therapeutics for $28.3bn, including debt, after the California-based biotech won a three-way race to secure a new pipeline of drugs for rare autoimmune and inflammatory diseases...
...Whereas at other pharma companies, reps often have quotas for how many doctors they visit a day, at Insys, they focused their time on their biggest targets....
...&D before selling anything....
...The opioid drugmaker Insys Therapeutics, whose products include the fentanyl-based spray Subsys, has filed for Chapter 11 bankruptcy in the wake of a $225m settlement with the US government....
...(FT, The Conversation, World Economic Forum, Jama) US opioid crisis A joint investigation between the FT and US broadcaster PBS tells the inside story of how executives from Insys became the first pharma...
...When Purdue Pharma settled a case in Oklahoma earlier this year, it included a letter of credit issued by a third party and a guarantee that enables it to access the settlement money even if the company...
...Insys filed for Chapter 11 bankruptcy just days after its settlement and Purdue Pharma has said it is considering bankruptcy. Are executives facing jail time?...
...As well as Insys, these include Purdue Pharma, the makers of OxyContin, and the large pharmaceutical company Johnson & Johnson, which is on trial in Oklahoma....
...Crispr is taking a very different tack. Its clinicians will make edits outside the body and in diseases that are well understood: blood disorders b-cell thalassaemia and sickle cell....
...Purdue Pharma, owned by the Sackler family, was also named as a defendant in that case but settled in March....
...Oklahoma’s victory may embolden other states to pursue J&J, which has deeper pockets than opioid makers like Purdue Pharma, which has said it is considering filing for bankruptcy, and Insys, which has already...
...While Purdue Pharma is considering bankruptcy, and fellow opioid maker Insys has already filed for Chapter 11, J&J’s much deeper pockets make it an attractive target for legal action....
...The day before I met Goldin in London, John Kapoor, the co-founder of Insys Therapeutics, which manufactured a fentanyl oral spray marketed as Subsys, was found guilty, along with four other executives,...
...GILD’s c$15bn cost base vs $11bn core op.income, of which c$5bn lies in R&D/SG&A), but also require very significant job cuts at a time of global economic hardship....
...Next up:Over the past two years, company D has spent an amount on buybacks equal to 85% of a year’s ebitda....
...The most promising experimental drug is from Nektar Therapeutics, a San Francisco biotech company that recently signed a record-breaking $1.85bn partnership deal with Bristol-Myers....
...One is Insys Therapeutics, a US biotech that generates revenues from opioids but spends a fifth of its research budget on cannabinoid drugs....
...Exhibit B is Martin “Pharma Bro” Shkreli. Only a guy who deludedly believes he’s cool smiles as broadly for the camera as the entrepreneur has in recent press photos....
...Enter Roddy Boyd of the Southern Investigative Reporting Foundation… Roddy is a longtime journalist and author of AIG, Fatal Risk. You should go read his story on Insys, published Monday, here....
...But the creation of Pfizergan will spawn something quite different: a sprawling pharmaceuticals behemoth with revenues of $65bn and more than 60 drugs — the kind of big pharma group that is so out of fashion...
...Nasdaq-listed Insys Therapeutics, whose drugs include a synthetic cannabidiol formulation, trades at 22 times forward earnings....
...small generics drugmaker known as Watson to one of the world’s biggest pharma groups....
...Amgen, the big US biotech group, in January agreed an R&D collaboration worth up to $585m with Kite Pharma, a Californian company that, together with Seattle-based Juno Therapeutics, is vying with Novartis...
International Edition